{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:38:44Z","timestamp":1788629924047,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01-HL139420"],"award-info":[{"award-number":["P01-HL139420"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.chembiol.2022.01.009","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T11:14:30Z","timestamp":1643800470000},"page":"215-225.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Generation of an anticoagulant aptamer that targets factor V\/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples"],"prefix":"10.1016","volume":"29","author":[{"given":"Erin E.","family":"Soule","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-9882","authenticated-orcid":false,"given":"Haixiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyra","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtehaj","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Krishnaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Sullenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2022.01.009_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.chembiol.2022.01.009_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1538-7836.2003.00151.x","article-title":"The discovery of Mary's mutation","volume":"1","author":"Asselta","year":"2003","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1160\/TH09-10-0716","article-title":"Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics","volume":"103","author":"Becker","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2022.01.009_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/355564a0","article-title":"Selection of single-stranded DNA molecules that bind and inhibit human thrombin","volume":"355","author":"Bock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2022.01.009_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/ALN.0b013e3181f22b5a","article-title":"Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution","volume":"113","author":"Bolliger","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.chembiol.2022.01.009_bib7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.chembiol.2014.05.016","article-title":"Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation","volume":"21","author":"Bompiani","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib8","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2174\/138920112802273137","article-title":"Antidote control of aptamer therapeutics: the road to a safer class of drug agents","volume":"13","author":"Bompiani","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib9","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1093\/nar\/gkv1479","article-title":"SimRNA: a coarse-grained method for RNA folding simulations and 3D structure prediction","volume":"44","author":"Boniecki","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2022.01.009_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1074\/jbc.M109.070334","article-title":"Regulated cleavage of prothrombin by prothrombinase: repositioning a cleavage site reveals the unique kinetic behavior of the action of prothrombinase on its compound substrate","volume":"285","author":"Bradford","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib11","doi-asserted-by":"crossref","first-page":"27789","DOI":"10.1074\/jbc.M113.502005","article-title":"Membrane binding by prothrombin mediates its constrained presentation to prothrombinase for cleavage","volume":"288","author":"Bradford","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib12","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1074\/jbc.M109.049833","article-title":"An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase","volume":"285","author":"Buddai","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib13","doi-asserted-by":"crossref","first-page":"30151","DOI":"10.1074\/jbc.M113.506840","article-title":"Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides","volume":"288","author":"Bunce","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib14","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/jth.13760","article-title":"A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release","volume":"15","author":"Burrell","year":"2017","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619888133","article-title":"Andexanet\u00a0alfa for reversal of factor Xa inhibitor-associated anticoagulation","volume":"10","author":"Carpenter","year":"2019","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.chembiol.2022.01.009_bib16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MOH.0000000000000452","article-title":"Emerging applications of aptamers for anticoagulation and hemostasis","volume":"25","author":"Chabata","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.90.3.1004","article-title":"Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C","volume":"90","author":"Dahlback","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.chembiol.2022.01.009_bib18","doi-asserted-by":"crossref","first-page":"0076","DOI":"10.1038\/s41570-017-0076","article-title":"Analysis of aptamer discovery and technology","volume":"1","author":"Dunn","year":"2017","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In\u00a0vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2022.01.009_bib20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0003-4975(00)01511-3","article-title":"Cardiopulmonary bypass in humans: bypassing unfractionated heparin","volume":"70","author":"Frederiksen","year":"2000","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.chembiol.2022.01.009_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.sbi.2016.01.009","article-title":"Embracing proteins: structural themes in aptamer-protein complexes","volume":"36","author":"Gelinas","year":"2016","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/(SICI)1096-8628(19971219)73:3<334::AID-AJMG20>3.0.CO;2-J","article-title":"Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations","volume":"73","author":"Gregg","year":"1997","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.chembiol.2022.01.009_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nbt.4153","article-title":"Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass","volume":"36","author":"Gunaratne","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5811\/westjem.2014.12.22933","article-title":"Anticoagulation drug therapy: a review","volume":"16","author":"Harter","year":"2015","journal-title":"West J. Emerg. Med."},{"key":"10.1016\/j.chembiol.2022.01.009_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-62703-339-8_12","article-title":"Activated clotting time (ACT)","volume":"992","author":"Horton","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood-2014-03-565010","article-title":"New insights into the spatiotemporal localization of prothrombinase in\u00a0vivo","volume":"124","author":"Ivanciu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2022.01.009_bib27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1055\/s-0037-1615962","article-title":"Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding","volume":"85","author":"Izumi","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nprot.2016.169","article-title":"The ClusPro web server for protein-protein docking","volume":"12","author":"Kozakov","year":"2017","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.chembiol.2022.01.009_bib29","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/S0021-9258(18)61503-0","article-title":"Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism","volume":"262","author":"Krishnaswamy","year":"1987","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/oli.2006.0059","article-title":"Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection","volume":"17","author":"Layzer","year":"2007","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.chembiol.2022.01.009_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.chembiol.2022.01.009_bib33","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1261\/rna.1239308","article-title":"Crystal structure of an RNA aptamer bound to thrombin","volume":"14","author":"Long","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.chembiol.2022.01.009_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/46594","article-title":"Crystal structures of the membrane-binding C2 domain of human coagulation factor V","volume":"402","author":"Macedo-Ribeiro","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2022.01.009_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2002-01-0290","article-title":"Factor V: a combination of Dr Jekyll and Mr Hyde","volume":"101","author":"Mann","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2022.01.009_bib36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report","volume":"158","author":"Moores","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.chembiol.2022.01.009_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.hrtlng.2020.03.012","article-title":"ECMO for ARDS due to COVID-19","volume":"49","author":"Namendys-Silva","year":"2020","journal-title":"Heart Lung"},{"key":"10.1016\/j.chembiol.2022.01.009_bib38","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.1990","article-title":"Development of universal antidotes to control aptamer activity","volume":"15","author":"Oney","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2022.01.009_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/oli.2007.0089","article-title":"Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers","volume":"17","author":"Oney","year":"2007","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.chembiol.2022.01.009_bib40","doi-asserted-by":"crossref","first-page":"13082","DOI":"10.1021\/bi050891t","article-title":"Completed three-dimensional model of human coagulation factor va. Molecular dynamics simulations and structural analyses","volume":"44","author":"Orban","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.chembiol.2022.01.009_bib41","doi-asserted-by":"crossref","first-page":"54927","DOI":"10.1074\/jbc.M410866200","article-title":"Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin","volume":"279","author":"Orcutt","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.12778","article-title":"Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"13","author":"Pabinger","year":"2015","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1055\/s-0037-1614127","article-title":"Three-dimensional model of coagulation factor Va bound to activated protein C","volume":"84","author":"Pellequer","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib44","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.chembiol.2022.01.009_bib45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0021-9258(19)86294-4","article-title":"The role of phospholipids and factor Va in the prothrombinase complex","volume":"255","author":"Rosing","year":"1980","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib46","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nbt1023","article-title":"Antidote-mediated control of an anticoagulant aptamer in\u00a0vivo","volume":"22","author":"Rusconi","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature00963","article-title":"RNA aptamers as reversible antagonists of coagulation factor IXa","volume":"419","author":"Rusconi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2022.01.009_bib48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1055\/s-0037-1614126","article-title":"Blocking the initiation of coagulation by RNA aptamers to factor VIIa","volume":"84","author":"Rusconi","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib49","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S2213-2600(20)30328-3","article-title":"Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study","volume":"8","author":"Schmidt","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.chembiol.2022.01.009_bib50","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40256-020-00431-z","article-title":"Current overview on hypercoagulability in COVID-19","volume":"20","author":"Singhania","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.chembiol.2022.01.009_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2015.0565","article-title":"Targeting two coagulation cascade proteases with a bivalent aptamer yields a potent and antidote-controllable anticoagulant","volume":"26","author":"Soule","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.chembiol.2022.01.009_bib52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1006\/jmbi.1997.1275","article-title":"Oligonucleotide inhibitors of human thrombin that bind distinct epitopes","volume":"272","author":"Tasset","year":"1997","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib53","doi-asserted-by":"crossref","first-page":"21643","DOI":"10.1074\/jbc.M402107200","article-title":"Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized","volume":"279","author":"Toso","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2022.01.009_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V60.1.59.59","article-title":"Radioimmunoassay of factor V in human plasma and platelets","volume":"60","author":"Tracy","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2022.01.009_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2022.01.009_bib56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1006\/mthe.2001.0495","article-title":"Generation of species cross-reactive aptamers using \"toggle\" SELEX","volume":"4","author":"White","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.chembiol.2022.01.009_bib57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/jth.12302","article-title":"Inhibiting the activation of the intrinsic pathway with a FXII-targeting RNA aptamer","volume":"11","author":"Woodruff","year":"2013","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.chembiol.2022.01.009_bib58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","article-title":"Generation and characterization of aptamers targeting factor XIa","volume":"156","author":"Woodruff","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.chembiol.2022.01.009_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11239-011-0578-5","article-title":"The many faces of the contact pathway and their role in thrombosis","volume":"32","author":"Woodruff","year":"2011","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.chembiol.2022.01.009_bib60","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1161\/ATVBAHA.115.300131","article-title":"Modulation of the coagulation cascade using aptamers","volume":"35","author":"Woodruff","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.chembiol.2022.01.009_bib61","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11239-008-0280-4","article-title":"Anticoagulant therapy during cardiopulmonary bypass","volume":"26","author":"Yavari","year":"2008","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.chembiol.2022.01.009_bib62","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic Acids Res."}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945622000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945622000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:41:33Z","timestamp":1762526493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945622000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2451945622000514"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2022.01.009","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation of an anticoagulant aptamer that targets factor V\/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2022.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}